Oncology Central

Approval granted for novel non-small cell lung cancer drug

The FDA has granted approval for Imfinzi®, one of AstraZeneca’s (Cambridge, UK) novel key therapeutic agents, making it the only immunotherapy approved for unresectable Stage III non-small cell lung cancer (NSCLC).
To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.